Real-World Data Show Zanubrutinib Delivers Strong Results in 410 Leukemia Patients

A large nationwide study from China has provided some of the most detailed real-world evidence yet on how patients with chronic lymphocytic leukemia and small lymphocytic lymphoma actually fare when treated with zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor. The analysis, published in BMC Cancer, followed 410 patients treated at regional centers across the country between September 2016 and March 2024, capturing the messy realities of clinical practice that randomized trials often miss: dose reductions, treatment interruptions, switches from competing drugs, and the personal decisions patients make about their own care. The headline finding is striking. After a median follow-up of 20.7 months, the three-year progression-free survival reached 91.6 percent among patients who received zanubrutinib as their initial therapy, and 83.2 percent among those who started it later in their treatment journey.

Zanubrutinib belongs to a class of targeted drugs known as Bruton’s tyrosine kinase inhibitors, or BTK inhibitors, which block a signaling protein that B cells, the immune cells that turn malignant in chronic lymphocytic leukemia, rely on for survival and proliferation. First-generation inhibitors such as ibrutinib transformed outcomes for this patient population but carried a burden of off-target effects, because they also inhibited related kinases including those involved in cardiac rhythm, platelet aggregation, and other signaling pathways. Zanubrutinib was engineered for greater selectivity, binding BTK more completely while sparing neighboring targets, and the new cohort study set out to test whether that improved pharmacological profile translates into better tolerability and sustained disease control outside the carefully curated environment of a clinical trial.

The researchers interrogated treatment patterns across the full cohort with unusual granularity. Therapy was discontinued in 76 patients, or 18.5 percent of the total, but the reasons tell an encouraging story. Disease progression accounted for only 32 discontinuations, or 7.8 percent of all patients, meaning the vast majority of patients who stopped the drug did so for reasons unrelated to treatment failure. Patient preference led 25 patients, or 6.1 percent, to discontinue, adverse events prompted 15 patients, or 3.7 percent, to stop, and four patients, or 1.0 percent, died of unknown causes. In an era when treatment duration on continuous oral therapy is a key measure of a drug’s real-world value, these numbers suggest that zanubrutinib keeps patients on treatment and keeps their disease in check for extended periods.

Perhaps the most clinically consequential finding concerns dose reductions, a topic that has generated anxiety among both oncologists and patients. Forty-six patients, or 11.2 percent of the cohort, required at least one dose reduction, most commonly because of adverse events, which affected 17 patients, or 4.1 percent, or because of patient preference, cited by 26 patients, or 6.3 percent. The critical question has always been whether lowering the dose compromises efficacy. The answer from this cohort appears to be no. Among the 46 patients who reduced their dose, the researchers observed no cases of disease progression or death after the reduction occurred, over a median follow-up of 10.9 months from the first dose modification. While the follow-up window is relatively short and the subgroup modest in size, the signal is reassuring for the many patients who need to taper their dose to manage side effects.

The study also shed light on a growing phenomenon in leukemia care: switching between BTK inhibitors. Fifty-four patients in the cohort moved to zanubrutinib from another BTK inhibitor without any evidence of disease progression, meaning they switched for tolerability or convenience rather than treatment failure. Thirty-two of these patients made the move because of adverse events on their previous drug, 19 because of patient preference, and four for unknown reasons, with some reasons overlapping. The median duration of zanubrutinib treatment after the switch was 10.1 months among patients who switched due to side effects and 16.5 months among those who switched by preference. Most notably, progression-free survival had not been reached in either group at the time of analysis, indicating that patients who transition from an older BTK inhibitor to zanubrutinib for non-progressive reasons can continue to achieve durable disease control on the newer agent.

From a technical standpoint, the study’s design merits attention. The investigators conducted a retrospective, multicenter cohort analysis drawing on data from hospitals across China, including Peking University People’s Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanfang Hospital, West China Hospital, and several others, with Peking University People’s Hospital serving as the central ethics committee. The primary endpoint was progression-free survival, the standard measure of how long patients live without their disease worsening, analyzed with confidence intervals to quantify uncertainty. The three-year PFS estimate of 91.6 percent for treatment-naive patients carried a 95 percent confidence interval of 83.8 to 95.8 percent, while the 83.2 percent estimate for later-line patients spanned 74.6 to 89.1 percent. These intervals, while wide in places due to the evolving follow-up time, place real-world outcomes squarely in the territory previously reported in registration trials, a consistency that strengthens confidence in the drug’s effectiveness.

The distinction between initial and later-line therapy matters enormously in chronic lymphocytic leukemia, an indolent malignancy that predominantly affects older adults and often follows a relapsing course over many years. Patients receiving zanubrutinib as initial therapy had not been exposed to prior BTK inhibition and typically had fewer accumulated resistance mechanisms. Those receiving it later had often been through chemoimmunotherapy or earlier targeted agents. The roughly eight-percentage-point gap in three-year progression-free survival between the two groups is consistent with the expected biology, yet the fact that later-line patients still achieved better than 83 percent freedom from progression at three years underscores how much the BTK inhibitor class has reshaped the prognosis of relapsed and refractory disease, which was historically one of the most difficult scenarios to manage.

Why does real-world evidence of this kind matter so much? Registration trials enroll selected patients, often excluding those with significant comorbidities, competing medications, or atypical disease features, and they monitor adherence intensively. Routine practice is different. Patients forget doses, stop drugs because they feel well, reduce doses on their own initiative, and switch therapies based on quality-of-life considerations that never appear in a case report form. By documenting that only 3.7 percent of patients discontinued zanubrutinib because of adverse events, and that dose reductions did not precipitate disease progression, this nationwide cohort provides the kind of pragmatic evidence that health systems, guideline committees, and prescribing physicians need when weighing treatment options for a disease that may require years of continuous oral therapy.

The findings also carry implications for how clinicians counsel patients about side effect management. Patient preference was the single most common reason for both dose reduction and discontinuation in this cohort, a reminder that shared decision-making is not a formality but a genuine determinant of treatment trajectories. Some patients in the study chose to reduce or stop their medication despite adequate tolerability, and the data suggest that, at least within the observed follow-up, such choices did not immediately translate into disease progression. That said, the authors and the broader hematology community would caution that longer observation is needed before dose attenuation can be considered fully equivalent to continuous full-dose therapy, particularly given the indolent nature of the disease and the possibility of late relapse.

Taken together, the study offers a comprehensive portrait of zanubrutinib as it is actually used: a drug with high selectivity for its target, low rates of discontinuation for toxicity, reassuring outcomes after dose modification, and strong progression-free survival in both first-line and later-line settings. As BTK inhibitors continue to evolve and as fixed-duration combinations challenge the paradigm of continuous therapy, cohorts like this one, registered as NCT06489184 on ClinicalTrials.gov, will remain essential for understanding how these powerful targeted agents perform in the hands of real patients and real physicians, far from the protocolized confines of the clinical trial.

Subject of Research: Real-world effectiveness, dose modification and discontinuation patterns of the BTK inhibitor zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma

Article Title: Dose modifications, discontinuation patterns and PFS of zanubrutinib in 410 CLL/SLL patients – a nationwide real-world cohort

Article References: Yang, S., Zhu, H., Hu, L., Feng, R., Guo, X., Niu, T., Shen, K., Li, Z., Dong, Y., Wang, B., Su, L., Wang, L., Wang, L., Sun, W., Fang, F., Zhao, Y., Huang, X., & Li, J. (2026). Dose modifications, discontinuation patterns and PFS of zanubrutinib in 410 CLL/SLL patients – a nationwide real-world cohort. BMC Cancer. https://doi.org/10.1186/s12885-026-17043-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17043-6

Keywords: zanubrutinib, chronic lymphocytic leukemia, small lymphocytic lymphoma, BTK inhibitor, progression-free survival, dose reduction, real-world evidence, drug discontinuation, adverse events, hematology, targeted therapy, BMC Cancer